Literature DB >> 23676959

Obstructive sleep apnea/hypopnea syndrome.

W De Backer1.   

Abstract

Obstructive sleep apnea/hypopnea syndrome (OSAHS) is characterized by recurrent episodes of partial or complete upper airway collapse during sleep that is highlighted by a reduction in, or complete cessation of, airflow despite documented on going inspiratory efforts. Due to the lack of adequate alveolar ventilation that results from the upper airway narrowing, oxygen saturation may drop and partial pressure of CO2 may occasionally increase. The events are mostly terminated by arousals. Clinical consequences are excessive daytime sleepiness related to the sleep disruption. Minimal diagnostic criteria have been defined for OSAHS. Patients should have excessive daytime sleepiness that can not be better explained by other factors, or experience two or more of the following symptoms, again that are not better explained by other factors: choking or gasping during sleep; recurrent awakenings from sleep; un-refreshing sleep; daytime fatigue; and impaired concentration. All patients should have more than five obstructed breathing events per hour during sleep. An obstructive apnea or hypopnoea can be defined as an event that lasts for ≥ 10 s and is characterized by an absence or a decrease from baseline in the amplitude of a valid measure of breathing during sleep that either reaches >50% with an oxygen desaturation of 3% or an arousal (alternatively a 30% reduction with 4% desaturation). The American Academy of Sleep Medicine (AASM) recommends these definitions. The Task Force of the AASM also states that there are common pathogenic mechanisms for obstructive apnea syndrome, central apnea syndrome, sleep hypoventilation syndrome and Cheyne-Stokes breathing. It was more preferable to discuss each of these separately; although, they could be placed under the common denominator of "sleep-disordered breathing syndrome". The definition of OSAHS using two components, daytime symptoms and breathing pattern disturbances during sleep, may suggest that there is a tight correlation between the two. However, unfortunately this is not the case. The breathing pattern abnormalities, mostly described by an Apnea/Hypopnoea Index (AHI), only weakly correlate with quantified measures of sleepiness, such as the Epworth Sleepiness Scale (ESS). This probably means that interindividual sensitivity, with some individuals coping better with sleep fragmentation than others, does compromise the relationship between the AHI and daytime sleepiness scores. In addition, epidemiological studies show a broad range of sleepiness in the general population. Obviously, epidemiological studies investigating the prevalence of OSAHS are all biased by the lack of a uniform definition. The prevalence of an AHI of >5 events · h-1 in a general population (without taking into account symptoms of sleepiness) has previously been estimated to be 24% in a male population. When symptoms of sleepiness were also taken into account, the prevalence decreased to 4% in males and 2% in females.

Entities:  

Mesh:

Year:  2013        PMID: 23676959

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  26 in total

1.  Clinical assessment and polysomnographic study of sleep apnea in a Chinese population of snorers.

Authors:  Chuan Shao; Jing-bo Jiang; Hong-cheng Wu; Shi-bo Wu; Bi-yun Yu; Yao-dong Tang
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

Review 2.  Beneficial effects of estrogens in obstructive sleep apnea hypopnea syndrome.

Authors:  Lixiu Zhang; Xiyan Ou; Tonggang Zhu; Xiaohong Lv
Journal:  Sleep Breath       Date:  2019-07-15       Impact factor: 2.816

3.  Adenotonsillectomy outcomes regarding bone age and osteocalcin in treatment of obstructive sleep apnea syndrome in children.

Authors:  Qing-Biao Zhang; Yin-Feng Li; Ming-Xiu Li; Ling-Yu Kong; Liang-Fu Jiang; Hui-Wei Feng; Xian-Liang Fan
Journal:  World J Pediatr       Date:  2016-11-15       Impact factor: 2.764

4.  Research on the Association Between Obstructive Sleep Apnea Hypopnea Syndrome Complicated With Coronary Heart Disease and Inflammatory Factors, Glycolipid Metabolism, Obesity, and Insulin Resistance.

Authors:  Yumei Wen; Haibin Zhang; Yu Tang; Rui Yan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-01       Impact factor: 6.055

5.  Detection of respiratory compromise by acoustic monitoring, capnography, and brain function monitoring during monitored anesthesia care.

Authors:  Pedro P Tanaka; Maria Tanaka; David R Drover
Journal:  J Clin Monit Comput       Date:  2014-01-14       Impact factor: 2.502

6.  Sleep apnoea adversely affects the outcome in patients who undergo posterior lumbar fusion: a population-based study.

Authors:  O Stundner; Y-L Chiu; X Sun; S-K Ramachandran; P Gerner; V Vougioukas; M Mazumdar; S G Memtsoudis
Journal:  Bone Joint J       Date:  2014-02       Impact factor: 5.082

7.  Relationship of obstructive sleep apnea and cardiometabolic risk factors in elderly patients with abdominal aortic aneurysm.

Authors:  Vittorio E Bianchi; William G Herbert; Jonathan Myers; Paul M Ribisl; Larry E Miller; Ronald L Dalman
Journal:  Sleep Breath       Date:  2014-09-10       Impact factor: 2.816

Review 8.  Therapeutic effects of different drugs on obstructive sleep apnea/hypopnea syndrome in children.

Authors:  Jing Zhang; Jie Chen; Yong Yin; Lei Zhang; Hao Zhang
Journal:  World J Pediatr       Date:  2017-10-20       Impact factor: 2.764

9.  Klotho alleviates chronic intermittent hypoxia-induced genioglossus myocyte apoptosis by inhibiting endoplasmic reticulum stress.

Authors:  Zhen Xue; Wenxiao Ding; Luyao Ge; Qiang Zhang
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

10.  The Association of Obstructive Sleep Apnea With Breast Cancer Incidence and Mortality: A Systematic Review and Meta-analysis.

Authors:  Dominic Wei Ting Yap; Nicole Kye Wen Tan; Benjamin Kye Jyn Tan; Yao Hao Teo; Veronique Kiak Mien Tan; Anna See; Song Tar Toh
Journal:  J Breast Cancer       Date:  2022-03-10       Impact factor: 2.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.